Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Acer’s pipeline includes four investigational programs: ACER-001 (sodium phenylbutyrate) for treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for treatment of induced Vasomotor Symptoms (iVMS); EDSIVO™ (celiprolol) for treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, Zika, dengue, Ebola and COVID-19. 

$ Additional capital required to support ACER-001 development (UCDs), and planned ACER-001 (MSUD), ACER-801 and EDSIVO™ clinical trials beyond Q4 2022

1 PDUFA target action date does not guarantee timing of decision by FDA

These pipeline products are under investigation and their safety and efficacy have not been established.  There is no guarantee that any of these products will receive health authority approval or become commercially available for the uses being investigated.